Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-BCMA-CAR-IL15 NK cells
- Development stage
- Preclinical
- Lead developer
- Korea Institute of Science and Technology
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
anti-BCMA-CAR-IL15 NK cells are genetically engineered allogeneic natural killer (NK) cells designed to target B-cell maturation antigen (BCMA) for the treatment of multiple myeloma. These cells are modified using lentiviral vectors to express a chimeric antigen receptor (CAR) targeting BCMA, alongside the co-expression of human interleukin-15 (IL-15). The integration of IL-15 is designed to enhance the persistence, proliferation, and in vivo survival of the CAR-NK cells without the need for exogenous cytokine support. Preclinical studies in multiple myeloma xenograft models have demonstrated that anti-BCMA-CAR-IL15 NK cells effectively eliminate myeloma cells in hematopoietic tissues such as the bone marrow, spleen, and blood, although they may show limited efficacy against extramedullary disease.
- Other names
- BCMA-CAR-IL15 NK cellsBCMA-CAR-IL-15 NK cellsBCMA-CAR-IL 15 NK cellsIL-15-armored anti-BCMA CAR NK cellsIL15-armored anti-BCMA CAR NK cellsIL 15-armored anti-BCMA CAR NK cellsanti-BCMA-CAR-IL15 natural killer cellsanti-BCMA-CAR-IL-15 natural killer cellsanti-BCMA-CAR-IL 15 natural killer cellsα-BCMA-CAR-IL15 NK cellsα-BCMA-CAR-IL15 natural killer cells
02
Targets
BCMA (B-cell maturation antigen)IL15 (Interleukin 15)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on anti-BCMA-CAR-IL15 NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-BCMA-CAR-IL15 NK cells.